Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vertex seeks broader use of CF drug Kalydeco

This article was originally published in Scrip

Executive Summary

Perhaps it was the distraction on the eve of a pending US government shutdown, which had Wall Street jittery on 30 September – with the Dow Jones, S&P 500 and Nasdaq all tumbling – but investors appeared to have mixed emotions over Vertex Pharmaceuticals' news it had submitted a supplemental new drug application (sNDA) to the US FDA to expand the labeling of Kalydeco (ivacaftor) as a monotherapy for cystic fibrosis (CF) patients 6 years or older who have at least one non-G551D gating mutation in the CF transmembrane conductance regulator (CFTR) gene.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC022949

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel